XML 53 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segments of Business and Geographic Areas
 9 Months Ended
Sep. 27, 2015
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas
SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

SALES BY SEGMENT OF BUSINESS
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
United States
 
$
1,277

 
1,173

 
8.9
 %
International
 
2,037

 
2,416

 
(15.7
)
Total
 
3,314

 
3,589

 
(7.7
)
Pharmaceutical
 
 
 
 
 
 
United States
 
4,509

 
4,723

 
(4.5
)
International
 
3,185

 
3,584

 
(11.1
)
Total
 
7,694

 
8,307

 
(7.4
)
Medical Devices
 
 
 
 
 
 
United States
 
3,005

 
2,946

 
2.0

International
 
3,089

 
3,625

 
(14.8
)
Total
 
6,094

 
6,571

 
(7.3
)
Worldwide
 
 
 
 
 
 
United States
 
8,791

 
8,842

 
(0.6
)
International
 
8,311

 
9,625

 
(13.7
)
Total
 
$
17,102

 
18,467

 
(7.4
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
United States
 
$
3,991

 
3,802

 
5.0
 %
International
 
6,196

 
7,088

 
(12.6
)
Total
 
10,187

 
10,890

 
(6.5
)
Pharmaceutical
 
 
 
 
 
 
United States
 
13,423

 
13,076

 
2.7

International
 
9,943

 
11,238

 
(11.5
)
Total
 
23,366

 
24,314

 
(3.9
)
Medical Devices
 
 
 
 
 
 
United States
 
8,980

 
9,300

 
(3.4
)
International
 
9,730

 
11,573

 
(15.9
)
Total
 
18,710

 
20,873

 
(10.4
)
Worldwide
 
 
 
 
 
 
United States
 
26,394

 
26,178

 
0.8

International
 
25,869

 
29,899

 
(13.5
)
Total
 
$
52,263

 
56,077

 
(6.8
)%


SEGMENT PRE-TAX PROFIT
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27,
2015
 
September 28,
2014
 
Percent
Change
Consumer (1)
 
$
811

 
407

 
99.3
 %
Pharmaceutical(2)
 
2,732

 
3,247

 
(15.9
)
Medical Devices(3)
 
835

 
3,399

 
(75.4
)
Segments operating profit
 
4,378

 
7,053

 
(37.9
)
Less: Expense not allocated to segments (4)
 
256

 
243

 
 
Worldwide income before taxes
 
$
4,122

 
6,810

 
(39.5
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
Consumer (1)
 
$
1,772

 
1,588

 
11.6
 %
Pharmaceutical(2)
 
9,816

 
9,921

 
(1.1
)
Medical Devices(3)
 
4,640

 
7,069

 
(34.4
)
Segments operating profit
 
16,228

 
18,578

 
(12.6
)
Less: Expense not allocated to segments (4)
 
790

 
718

 
 
Worldwide income before taxes
 
$
15,438

 
17,860

 
(13.6
)%

(1) Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014.

(2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014.
(3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASRTM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal nine months of 2014.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
SALES BY GEOGRAPHIC AREA
 
 
Fiscal Third Quarters Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
United States
 
$
8,791

 
8,842

 
(0.6
)%
Europe
 
3,802

 
4,446

 
(14.5
)
Western Hemisphere, excluding U.S.
 
1,463

 
1,820

 
(19.6
)
Asia-Pacific, Africa
 
3,046

 
3,359

 
(9.3
)
Total
 
$
17,102

 
18,467

 
(7.4
)%

 
 
 
 
 
 
 
 
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 27, 2015
 
September 28, 2014
 
Percent
Change
United States
 
$
26,394

 
26,178

 
0.8
 %
Europe
 
11,993

 
14,387

 
(16.6
)
Western Hemisphere, excluding U.S.
 
4,603

 
5,378

 
(14.4
)
Asia-Pacific, Africa
 
9,273

 
10,134

 
(8.5
)
Total
 
$
52,263

 
56,077

 
(6.8
)%